Clinical Trial Update: Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update summarizing Phase 2/3 results of rapamycin (sirolimus) for autosomal dominant polycystic kidney disease and the use of biomarkers to pre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Yale University | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2014-04-14